{"id":28001,"date":"2022-07-14T18:25:00","date_gmt":"2022-07-14T10:25:00","guid":{"rendered":"https:\/\/flcube.com\/?p=28001"},"modified":"2025-02-25T18:27:18","modified_gmt":"2025-02-25T10:27:18","slug":"shanghai-ark-bio-raises-series-d-funding-to-advance-pediatric-and-respiratory-drug-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=28001","title":{"rendered":"Shanghai Ark Bio Raises Series D Funding to Advance Pediatric and Respiratory Drug Pipeline"},"content":{"rendered":"\n

China-based Shanghai Ark Biopharmaceutical Co., Ltd has completed a Series D financing round, following its Series C round in January 2021. The latest round was led by Loyal Valley Capital and included participation from C&D Emerging Industry Equity Investment, Longda Foods, and existing investors such as Oriza Holdings, Qiming Venture Partners, Shanghai Free Trade Zone Equity Investment Fund Management, Lingang New Area Science and Technology Innovation Fund, and Oriental Fortune Capital.<\/p>\n\n\n\n

Company Profile<\/strong>
Founded in 2014, Ark Bio focuses on pediatrics and respiratory diseases. Its core product, AK0529, an anti-respiratory syncytial virus (RSV) drug licensed from Roche in 2014, has completed global Phase III trials with positive results. The company’s ADHD treatment Azstarys (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]), licensed from Switzerland’s Commave Therapeutics SA in a $105.5 million deal in December 2023, received US market approval.<\/p>\n\n\n\n

Strategic Partnerships<\/strong>
Ark Bio has collaborations with multinational pharma firms Roche and Genentech, as well as top academic institutions like the Scripps Institute and the Chinese Academy of Sciences’ Institute of Microbiology.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Shanghai Ark Biopharmaceutical Co., Ltd has completed a Series D financing round, following its…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1443,30,20],"class_list":["post-28001","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-ark-biopharmaceutical","tag-biotech","tag-finance"],"yoast_head":"\nShanghai Ark Bio Raises Series D Funding to Advance Pediatric and Respiratory Drug Pipeline - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Shanghai Ark Biopharmaceutical Co., Ltd has completed a Series D financing round, following its Series C round in January 2021. The latest round was led by Loyal Valley Capital and included participation from C&D Emerging Industry Equity Investment, Longda Foods, and existing investors such as Oriza Holdings, Qiming Venture Partners, Shanghai Free Trade Zone Equity Investment Fund Management, Lingang New Area Science and Technology Innovation Fund, and Oriental Fortune Capital.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=28001\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai Ark Bio Raises Series D Funding to Advance Pediatric and Respiratory Drug Pipeline\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=28001\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-14T10:25:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-25T10:27:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28001#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28001\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai Ark Bio Raises Series D Funding to Advance Pediatric and Respiratory Drug Pipeline\",\"datePublished\":\"2022-07-14T10:25:00+00:00\",\"dateModified\":\"2025-02-25T10:27:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28001\"},\"wordCount\":185,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Ark Biopharmaceutical\",\"Biotech\",\"Finance\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=28001#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28001\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=28001\",\"name\":\"Shanghai Ark Bio Raises Series D Funding to Advance Pediatric and Respiratory Drug Pipeline - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-07-14T10:25:00+00:00\",\"dateModified\":\"2025-02-25T10:27:18+00:00\",\"description\":\"China-based Shanghai Ark Biopharmaceutical Co., Ltd has completed a Series D financing round, following its Series C round in January 2021. The latest round was led by Loyal Valley Capital and included participation from C&D Emerging Industry Equity Investment, Longda Foods, and existing investors such as Oriza Holdings, Qiming Venture Partners, Shanghai Free Trade Zone Equity Investment Fund Management, Lingang New Area Science and Technology Innovation Fund, and Oriental Fortune Capital.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28001#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=28001\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28001#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai Ark Bio Raises Series D Funding to Advance Pediatric and Respiratory Drug Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai Ark Bio Raises Series D Funding to Advance Pediatric and Respiratory Drug Pipeline - Insight, China's Pharmaceutical Industry","description":"China-based Shanghai Ark Biopharmaceutical Co., Ltd has completed a Series D financing round, following its Series C round in January 2021. The latest round was led by Loyal Valley Capital and included participation from C&D Emerging Industry Equity Investment, Longda Foods, and existing investors such as Oriza Holdings, Qiming Venture Partners, Shanghai Free Trade Zone Equity Investment Fund Management, Lingang New Area Science and Technology Innovation Fund, and Oriental Fortune Capital.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=28001","og_locale":"en_US","og_type":"article","og_title":"Shanghai Ark Bio Raises Series D Funding to Advance Pediatric and Respiratory Drug Pipeline","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=28001","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-07-14T10:25:00+00:00","article_modified_time":"2025-02-25T10:27:18+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=28001#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=28001"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai Ark Bio Raises Series D Funding to Advance Pediatric and Respiratory Drug Pipeline","datePublished":"2022-07-14T10:25:00+00:00","dateModified":"2025-02-25T10:27:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=28001"},"wordCount":185,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Ark Biopharmaceutical","Biotech","Finance"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=28001#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=28001","url":"https:\/\/flcube.com\/?p=28001","name":"Shanghai Ark Bio Raises Series D Funding to Advance Pediatric and Respiratory Drug Pipeline - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-07-14T10:25:00+00:00","dateModified":"2025-02-25T10:27:18+00:00","description":"China-based Shanghai Ark Biopharmaceutical Co., Ltd has completed a Series D financing round, following its Series C round in January 2021. The latest round was led by Loyal Valley Capital and included participation from C&D Emerging Industry Equity Investment, Longda Foods, and existing investors such as Oriza Holdings, Qiming Venture Partners, Shanghai Free Trade Zone Equity Investment Fund Management, Lingang New Area Science and Technology Innovation Fund, and Oriental Fortune Capital.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=28001#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=28001"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=28001#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai Ark Bio Raises Series D Funding to Advance Pediatric and Respiratory Drug Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/28001","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=28001"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/28001\/revisions"}],"predecessor-version":[{"id":28002,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/28001\/revisions\/28002"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=28001"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=28001"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=28001"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}